Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 8, 2015

Study Completion Date

September 8, 2015

Conditions
Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated CarcinomaRecurrent Uterine Corpus Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Trametinib

Given PO

DRUG

Uprosertib

Given PO

Trial Locations (22)

10065

Memorial Sloan Kettering Cancer Center, New York

19107

Thomas Jefferson University Hospital, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

22908

University of Virginia Cancer Center, Charlottesville

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

28203

Carolinas Medical Center/Levine Cancer Institute, Charlotte

29425

Medical University of South Carolina, Charleston

30912

Augusta University Medical Center, Augusta

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

44106

Case Western Reserve University, Cleveland

44124

Hillcrest Hospital Cancer Center, Mayfield Heights

44195

Cleveland Clinic Foundation, Cleveland

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

73104

University of Oklahoma Health Sciences Center, Oklahoma City

77030

M D Anderson Cancer Center, Houston

87102

University of New Mexico Cancer Center, Albuquerque

06102

Hartford Hospital, Hartford

06050

The Hospital of Central Connecticut, New Britain

02905

Women and Infants Hospital, Providence

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NRG Oncology

OTHER

lead

National Cancer Institute (NCI)

NIH

NCT01935973 - Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | Biotech Hunter | Biotech Hunter